Drug shortage
Betaxolol Hydrochloride Ophthalmic Suspension · Novartis Pharmaceuticals Corporation
FDA drug shortage · To Be Discontinued · updated Jul 2, 2024
Key facts
| Generic name | Betaxolol Hydrochloride Ophthalmic Suspension |
|---|---|
| Proprietary name | Betoptic S |
| Company | Novartis Pharmaceuticals Corporation |
| Presentation | Betoptic S, Ophthalmic Suspension, 2.8 mg/1 mL (NDC 0078-0729-10) |
| Dosage form | Ophthalmic Suspension |
| Strength | 2.8 mg/1 mL |
| Status | To Be Discontinued |
| Therapeutic category | Ophthalmology |
| Package NDCs | 0078-0729-10 |
| First posted | Jul 2, 2024 |
| Last updated | Jul 2, 2024 |
| Discontinued | Jul 2, 2024 |
At a glance
- 1–9 Package NDCs affected
- 1–9 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: